There are more than 100,000 strokes in the UK each year. Almost two-thirds of stroke survivors leave hospital with a disability and in need of rehabilitation, with arms and hands most commonly affected.
Through his digital health startup Neurofenix, Guillem Singla Buxarrais is seeking to increase the accessibility and effectiveness of post-stroke rehabilitation with the NeuroBall, a novel and cost-effective medical device making bold changes to stroke rehabilitation.
Physiotherapy exercises can be repetitive and boring, whereas the Neuroball encourages users to exercise the whole arm, from shoulder to fingers, through a set of entertaining games, keeping the user engaged in their therapy.
Engineered with stroke survivors and physiotherapists from inception, the mobile application and handheld controller is a user-friendly device that helps people to regain function in an enjoyable way, as verified in user testing.
Guillem’s experience of volunteering in stroke rehabilitation motivated him to ensure that stroke survivors and physiotherapists were involved with the engineering of the device from inception. The mobile application and handheld controller is user-friendly and helps people to regain function in an enjoyable way, as verified in user testing.
The Neuroball has been engineered to sensitively monitor recovery. It shows stroke survivors their progress, and they can share results with a supportive online community, helping them to feel re-connected with family, friends and other survivors.
Guillem was awarded a 2017 Enterprise Fellowship supported by the Royal Commission for the Exhibition of 1851 to continue developing this technology and the Neurofenix team has grown rapidly as a result. It is also supported by the Nominet Trust and Entrepreneur First.
"The Enterprise Fellowship had a profound impact on Neurofenix’s progress and reducing our time to market. Our mentor and the Enterprise team provided invaluable support throughout."